
Accelerant Holdings Announces Closing of Upsized Initial Public Offering and Full Exercise of Over-Allotment Option
Morgan Stanley & Co. LLC acted as lead left active bookrunner, Goldman Sachs & Co. LLC acted as lead right active bookrunner, and BMO Capital Markets Corp. and RBC Capital Markets, LLC acted as active bookrunners for the offering. Wells Fargo Securities, LLC; Piper Sandler & Co.; William Blair & Company, L.L.C.; Raymond James & Associates, Inc.; and TD Securities (USA) LLC acted as bookrunners. Citizens Capital Markets and FT Partners acted as co-managers.
The offering of Accelerant's Common Shares was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the U.S. Securities and Exchange Commission's (the 'SEC') website at www.sec.gov. Alternatively, copies of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, by telephone at (800) 414-3627, or by email at bmoprospectus@bmo.com; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.
A registration statement on Form S-1 relating to the Common Shares was declared effective by the SEC on July 23, 2025. This press release does not constitute an offer to sell or the solicitation of an offer to buy Common Shares, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
ABOUT ACCELERANT
Accelerant is a data-driven risk exchange connecting underwriters of specialty insurance risk with risk capital providers. Accelerant was founded in 2018 by a group of longtime insurance industry executives and technology experts who shared a vision of rebuilding the way risk is exchanged – so that it works better, for everyone. The Accelerant risk exchange does business across 22 different countries and more than 500 specialty insurance products.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Bitcoin-To-Ethereum Rotation: Genius Move Or FOMO Trap? Here's What The Data Shows
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. As Ethereum trades near multi-month highs and Bitcoin's dominance faces fresh challenges, the ETH/BTC ratio is currently sitting at 0.058, sparking intense debate on Reddit among crypto veterans about whether now is the time to rotate capital from Bitcoin into Ethereum for potential alt season gains. The strategy—known in crypto circles as 'the rotation'—involves temporarily swapping Bitcoin holdings for Ethereum during periods when altcoins typically outperform the flagship cryptocurrency, then rotating back to Bitcoin after capturing those gains. It's a high-stakes game of market timing that has created generational wealth for some traders while leaving others with costly tax bills and diminished holdings. Don't Miss: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— — no wallets, just price speculation and free paper trading to practice different strategies. The Case for Making the Move Proponents of the Bitcoin-to-Ethereum rotation point to compelling historical patterns and current market dynamics that suggest significant upside potential for ETH relative to BTC. Over the past 90 days, Ethereum has dramatically outpaced Bitcoin with a 102% gain compared to Bitcoin's more modest 22% advance, demonstrating the kind of explosive relative performance that rotation traders seek. The fundamental case for Ethereum has strengthened considerably, particularly with the Genius Act legislation accelerating institutional adoption of stablecoins—90% of which operate on Ethereum's network. This regulatory tailwind, combined with Ethereum's transition to a deflationary monetary policy since moving to proof-of-stake, creates a compelling structural argument for continued outperformance. Galaxy Research projects the ETH/BTC ratio could reach between 0.03 and 0.045, suggesting substantial room for growth from current levels. For context, the ratio has historically peaked much higher during previous market cycles, with some traders targeting ranges between 0.049 to 0.088 based on technical analysis of past bull markets. Trending: Grow your IRA or 401(k) with Crypto – . Tax-conscious investors have found creative workarounds to execute this strategy without triggering immediate capital gains. By using lending protocols to collateralize Bitcoin holdings and borrow stablecoins or additional Bitcoin to purchase Ethereum, traders can gain ETH exposure while maintaining their original BTC position on paper—though this approach carries its own risks around loan-to-value ratios and liquidation scenarios. The Bear Case: Too Late to the Party? However, seasoned crypto veterans are increasingly cautioning that the optimal entry window for this rotation may have already closed. After Ethereum's 100% surge over the past three months, critics argue that attempting the swap now amounts to 'FOMOing' into an already extended move. The margin of error for timing the eventual rotation back to Bitcoin has become significantly tighter compared to earlier opportunities when Ethereum traded below $2,000. Bitcoin maximalists maintain that BTC remains the superior long-term store of value, pointing to year-to-date performance where Bitcoin is up 25% compared to Ethereum's 11% gain. Market structure concerns add another layer of complexity. The ETH/BTC ratio recently dropped to 0.022, its lowest level since 2020, and some analysts worry that the 2017-style altcoin euphoria that drove massive relative outperformance may not materialize in the current institutional-dominated market lending protocol strategy that appeals to tax-sensitive investors carries substantial risks, particularly the possibility of liquidation if Ethereum fails to perform as expected or if Bitcoin experiences an unexpected rally. Given Bitcoin's tendency for sudden, explosive moves, traders could find themselves 'stuck with debt' while watching their collateralized Bitcoin appreciate without them. The Verdict: Risk Management Over FOMO For retail investors considering this strategy, the key consideration isn't whether Ethereum might outperform Bitcoin—it very well could. The critical question is whether the potential gains justify the risks of market timing, tax implications, and the possibility of missing Bitcoin's continued institutional adoption cycle. The safest approach may be gradual portfolio rebalancing rather than wholesale rotation, allowing investors to maintain exposure to both assets while managing downside risks. As one seasoned trader noted, 'In crypto, permanent capital beats performance chasing.' Those determined to execute a rotation strategy should consider starting with smaller position sizes and maintaining strict exit rules, remembering that in previous cycles, the window between altcoin peaks and Bitcoin resuming its dominance has often been measured in weeks, not months. Read Next: A must-have for all crypto enthusiasts: . Image: Shutterstock This article Bitcoin-To-Ethereum Rotation: Genius Move Or FOMO Trap? Here's What The Data Shows originally appeared on


Business Upturn
a day ago
- Business Upturn
GHV Infra secures Rs 2,645 crore EPC contract for smart manufacturing hub in UAE
By Aman Shukla Published on August 2, 2025, 11:32 IST GHV Infra Projects Limited has announced that it has secured a major international contract for the development of a large-scale industrial and commercial hub in the United Arab Emirates (UAE). The company has received a Letter of Award (LOA) from Rana Exim FZ-LLC, a registered entity at Ras Al Khaimah Economic Zone (RAKEZ), UAE. Under this engineering, procurement, and construction (EPC) contract, GHV Infra Projects will undertake the full development of the 'Erisha Smart Manufacturing Hub,' which will consist of state-of-the-art industrial and commercial buildings. The total project value stands at approximately ₹2,645 crore (AED 1.12 billion). The construction is expected to be completed within 24 months, excluding an initial 90-day mobilization and setup period. This contract marks a significant step for GHV Infra Projects in expanding its international footprint. It is worth noting that this is an overseas order, with no related party involvement, and has been awarded by a non-domestic entity. There is no promoter or group company interest in the awarding entity, and the transaction does not fall under related party contracts. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
a day ago
- Yahoo
Citi Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data